A carregar...

Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies

PURPOSE: To provide dermatologists and oncologists with a foundation for practical understanding and uses of 5α-reductase inhibitors and spironolactone for breast cancer patients and survivors receiving endocrine therapies, including the effect of these treatments on sex hormone levels, any reported...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Rozner, Raquel N., Freites-Martinez, Azael, Shapiro, Jerry, Geer, Eliza B., Goldfarb, Shari, Lacouture, Mario
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6773272/
https://ncbi.nlm.nih.gov/pubmed/30467659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-018-4996-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!